-Elacestrant single agent Objective Response Rate (ORR) was 23% in heavily pre-treated patients with advanced ER+ breast cancer at the cut off date of April 28, 2017- -In the 400 mg patient group with mature data, median PFS was 4.5 months and Clinical Benefit Rate at 24 weeks was 42%- -38% of these patients previously …
The post Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO) appeared first on ForexTV.
June 04, 2017 at 06:49PM
from Nasdaq NewsFeed
No comments:
Post a Comment